Anti PD-L1s continue lacklustre rivalry with anti PD-1s

AstraZeneca received accelerated FDA approval for its anti PD-L1 durvalumab (Imfinzi) in 2nd line bladder cancer last week, making this the second anti PD-L1 approved in this cancer and, along with anti PD1 Opdivo, the third checkpoint inhibitor approved overall. Merck’s Keytruda is also expected to gain approved following its overall survival benefit vs chemo in the phase III KEYNOTE 45 study. However the FDA label continues to add the growing body of evidence that PDL1s are not quite the same as PD1s...